EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Glomerular Filtration Rate (GFR) Estimation with Cystatin C—Past, Present, and Future

Amy B Karger iD, Michael G Shlipak

Clinical Chemistry · 04.07.2025 · 71 (7) · 743-751

DOI: 10.1093/clinchem/hvae226 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Chemistry, online erschienen am 04.02.2025. Verfasst von Amy B Karger und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine & Pathology, University of Minnesota, Minneapolis, MN, United States. Hauptthemen laut MEDLINE: Cystatin C, Glomerular Filtration Rate. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 58 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Cystatin C is a long-established filtration marker which can be used to assess kidney function, but it has been sparingly used for clinical care due to creatinine’s role as the primary biomarker for kidney function assessment based on estimated glomerular filtration rate (eGFR). Content This review summarizes the evolution of cystatin C’s role in kidney disease assessment and highlights new guidelines promoting more widespread use. Specifically, the 2021 National Kidney Foundation and American Society of Nephrology Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease report, and the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), recommend increased use of cystatin C as an alternative and complementary biomarker for kidney function assessment, since it does not differ by race like creatinine, correlates better with adverse outcomes compared to creatinine, and provides a more accurate eGFR when used in combination with creatinine. Summary While robust literature demonstrates improved accuracy with cystatin C-based eGFR (eGFRcys) in certain clinical subpopulations, future research is needed to better understand its performance relative to creatinine-based eGFR (eGFRcr) and measured glomerular filtration rate (mGFR) in additional diverse cohorts, and to achieve assay standardization to match the performance of creatinine assays. Additionally, cystatin C testing availability will need to be broadened from primarily reference laboratories to local laboratories, and partnerships will need to be developed between clinical stakeholders and the laboratory to promote cystatin C’s clinical use, to achieve widespread adoption of guideline-recommended eGFR equations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystatin CGlomerular Filtration RateHumansBiomarkersRenal Insufficiency, ChronicCreatininePractice Guidelines as Topic

Substanzen

Cystatin CBiomarkersCreatinine

Autor:innen und Institutionen

  • Department of Laboratory Medicine & Pathology, University of Minnesota, Minneapolis, MN, United States.
  • Kidney Health Research Collaborative, University of California San Francisco, San Francisco VA Healthcare System, San Francisco, CA, United States.

ORCID-Profile: Amy B Karger

Zitieren

APA

Karger, A. B., & Shlipak, M. G. (2025). Glomerular Filtration Rate (GFR) Estimation with Cystatin C—Past, Present, and Future. Clinical Chemistry, 71(7), 743-751. https://doi.org/10.1093/clinchem/hvae226

Vancouver

Karger AB, Shlipak MG. Glomerular Filtration Rate (GFR) Estimation with Cystatin C—Past, Present, and Future. Clinical Chemistry. 2025;71(7):743-751. doi:10.1093/clinchem/hvae226

BibTeX
@article{Karger2025,
  author = {Karger, Amy B and Shlipak, Michael G},
  title = {Glomerular Filtration Rate (GFR) Estimation with Cystatin C—Past, Present, and Future},
  journal = {Clinical Chemistry},
  year = {2025},
  volume = {71},
  number = {7},
  pages = {743--751},
  doi = {10.1093/clinchem/hvae226}
}
Kostenlos starten →